NADpricesA clearer way to compare NAD+

NAD Prices

Editorial policy

How sellers get into the index

A seller is listed if it publicly sells NAD+ to U.S. buyers and publishes enough for a price to be read from its own pages. Nothing else qualifies or disqualifies it. Whether aseller pays this site is not part of that test: no row was added because of a commercial relationship, and most of the sellers listed pay this site nothing. What a commercial relationship does change is where a seller sits in a list, and only that — Some sellers on the index pay this site a commission. They are grouped first and marked “Partner”; payment affects display order, not scores or prices. It is set out in full on the disclosure page. The current rows are on the NAD+ price index.

How a price is read

I read the figure from the seller’s own public pages and record it with that day’s date. Where a price only appears part-way through an intake, I walk the intake far enough to see it, and record what the page actually showed.

The qualifier is recorded with the number, because without it the number is not a price. A “from” or “starting at” figure is a floor and is stored as one; it can never be published as a rate. A prepay total is stored as a total with its term, and no monthly figure is divided out of it — if a seller’s own “equivalent to $X/month” does not divide, both figures get printed and the discrepancy gets said out loud. A month is not a month until the page says so: 28 days, four weeks, per shipment and prepay are four different things and each is named.

I do not name a cheapest seller from a figure a script scraped out of prose. A ranking claim needs a figure I have read and can point at.

How often it is re-read

A freshness badge is a claim; a reading date is a fact, so every figure on this site carries its own reading date instead of a badge. When a re-reading schedule is set, it gets stated here, in this section, as a commitment.

The cadence is not yet fixed. Until it is stated here as a commitment, treat the reading date on each row as the only claim being made about how current it is.

What a change means here

A change is only shown between two readings this site took. Nothing is inferred from a seller’s announcement, an archived page or a competitor’s figure, and no gap in the series is filled in. Where there is one reading, the row says so in those words — it names the month it was read and states that no change can be shown until this site reads that seller again. It does not say the price held: that would be a claim about price stability I have not observed, and it is the one sentence this site must never print. A build check fails the build if the one-word version of that claim — the word a price table reaches for when it has nothing to put in a diff — reaches a reader anywhere on this site while no seller here has two readings at the same figure. That check tests for that one word, not for every synonym of it; the rest is editorial discipline, and it is stated here as discipline rather than dressed up as a machine.

Direction is shown by a sign and a glyph, never by color. A rise is not a loss to the person reading this, and a red-and-green index is unreadable to a color-blind buyer.

What a commercial relationship changes

It changes where a seller’s card sits: sellers that pay this site are grouped first on a board and marked with a small text label, and the board’s own order runs inside that group and below it. It also changes the wording of the disclosure beside the link. It does not change the figure, the qualifier, the reading date, or how the seller is described. The arrangement itself, and the full list of what it cannot touch, is on the disclosure page.

Mistakes

When a figure here is wrong, it gets corrected on the page and logged on corrections with what was wrong, when it was published, and when it was fixed. A seller telling us its price “starts at” something is a lead to re-read the seller, not a price to publish.

What this site does not do

It does not review products clinically, recommend a dose, or tell anyone whether to take NAD+. Nothing on it is medically reviewed, and nothing on it is medical advice. See the medical disclaimer and about.